Patents by Inventor Douglas Frantz
Douglas Frantz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140364467Abstract: The present invention relates to compounds and methods for inducing neuronal differentiation in normal neural stem cells and brain cancer stem cells. The methods may take place in vitro, such as in isolates from the adult mammalian brain, or in vivo. Compounds and methods described herein may find use in the treatment of neurodegenerative and psychiatric diseases, the repair and regeneration of the nervous system, and in treatment of neurologic malignancy.Type: ApplicationFiled: June 20, 2014Publication date: December 11, 2014Applicant: The Board of Regents of the University of Texas SystemInventors: Jay Schneider, Jenny Hsieh, Douglas Frantz, Steven L. McKnight, Joseph M. Ready
-
Patent number: 8778940Abstract: The present invention relates to compounds and methods for inducing neuronal differentiation in normal neural stem cells and brain cancer stem cells. The methods may take place in vitro, such as in isolates from the adult mammalian brain, or in vivo. Compounds and methods described herein may find use in the treatment of neurodegenerative and psychiatric diseases, the repair and regeneration of the nervous system, and in treatment of neurologic malignancy.Type: GrantFiled: June 4, 2012Date of Patent: July 15, 2014Assignee: The Board of Regents of the University of Texas SystemInventors: Jay Schneider, Jenny Hsieh, Douglas Frantz, Steven L. McKnight, Joseph M. Ready
-
Patent number: 8686012Abstract: The present invention relates to screens for compounds that can induce stem cell differentiation. In addition, isoxazoles and sulfonyl hydrazones are identified as general classes of compounds that can induce differentiation of stem cells into cells of neuronal and cardiac fate, respectively.Type: GrantFiled: November 12, 2012Date of Patent: April 1, 2014Assignee: The Board of Regents of the University of Texas SystemInventors: Eric N. Olson, Douglas Frantz, Jenny Hsieh, Steven L. McKnight, Jay Schneider
-
Patent number: 8660855Abstract: Embodiments of the present invention relate to methods and apparatuses serving to provide assurance that healthcare providers will receive payment for services rendered. In one embodiment, a payment card (or other portable consumer device) provides an extended authorization hold period (for example up to 21 days). This hold period allows the healthcare provider to request authorization for payment from the patient's credit, debit, FSA, HRA, or HSA payment card, submit the insurance claim, and then upon receipt of a health insurance carrier's Explanation of Benefits (EOB) within the hold period, submit for settlement only that amount actually due from the patient. In accordance with an alternative embodiment, pending receipt of the EOB from the insurer, the healthcare provider flags a transaction in a point-of-sale (POS) terminal device or server for storage and delayed submittal over an electronic payment network.Type: GrantFiled: June 8, 2007Date of Patent: February 25, 2014Assignee: VISA U.S.A. Inc.Inventors: Stacy Pourfallah, Janet Pruitt, Douglas Frantz, Roxanna Kayoumi
-
Publication number: 20130143885Abstract: The present invention relates to compounds and methods for inducing neuronal differentiation in normal neural stem cells and brain cancer stem cells. The methods may take place in vitro, such as in isolates from the adult mammalian brain, or in vivo. Compounds and methods described herein may find use in the treatment of neurodegenerative and psychiatric diseases, the repair and regeneration of the nervous system, and in treatment of neurologic malignancy.Type: ApplicationFiled: June 4, 2012Publication date: June 6, 2013Applicant: The Board of Regents of the University of Texas SystemInventors: Jay Schneider, Jenny Hsieh, Douglas Frantz, Steven L. McKnight, Joseph M. Ready
-
Patent number: 8318951Abstract: The present invention relates to screens for compounds that can induce stem cell differentiation. In addition, isoxazoles and sulfonyl hydrazones are identified as general classes of compounds that can induce differentiation of stem cells into cells of neuronal and cardiac fate, respectively.Type: GrantFiled: May 26, 2011Date of Patent: November 27, 2012Assignee: The Board of Regents of the University of Texas SystemInventors: Eric N. Olson, Douglas Frantz, Jenny Hsieh, Steven L. McKnight, Jay Schneider
-
Patent number: 8193225Abstract: The present invention relates to compounds and methods for inducing neuronal differentiation in normal neural stem cells and brain cancer stem cells. The compounds are isoxazole amides and derivatives thereof. The methods may take place in vitro, such as in isolates from the adult mammalian brain, or in vivo. Compounds and methods described herein may find use in the treatment of neurodegenerative and psychiatric diseases, the repair and regeneration of the nervous system, and in treatment of neurologic malignancy.Type: GrantFiled: October 12, 2007Date of Patent: June 5, 2012Assignee: The Board of Regents of the University of Texas SystemInventors: Jay Schneider, Jenny Hsieh, Douglas Frantz, Steven L. McKnight, Joseph M. Ready
-
Publication number: 20120029200Abstract: The present invention relates to screens for compounds that can induce stem cell differentiation. In addition, isoxazoles and sulfonyl hydrazones are identified as general classes of compounds that can induce differentiation of stem cells into cells of neuronal and cardiac fate, respectively.Type: ApplicationFiled: May 26, 2011Publication date: February 2, 2012Inventors: Eric N. Olson, Douglas Frantz, Jenny Hsieh, Steven L. McKnight, Jay Schneider
-
Patent number: 7981935Abstract: The present invention relates to screens for compounds that can induce stem cell differentiation. In addition, isoxazoles and sulfonyl hydrazones are identified as general classes of compounds that can induce differentiation of stem cells into cells of neuronal and cardiac fate, respectively.Type: GrantFiled: July 31, 2008Date of Patent: July 19, 2011Assignee: The Board of Regents of the University of Texas SystemInventors: Eric Olson, Douglas Frantz, Jenny Hsieh, Steven L. McKnight, Jay Schneider
-
Publication number: 20090076103Abstract: The present invention relates to screens for compounds that can induce stem cell differentiation. In addition, isoxazoles and sulfonyl hydrazones are identified as general classes of compounds that can induce differentiation of stem cells into cells of neuronal and cardiac fate, respectively.Type: ApplicationFiled: July 31, 2008Publication date: March 19, 2009Inventors: Eric Olson, Douglas Frantz, Jenny Hsieh, Steven L. McKnight, Jay Schneider
-
Publication number: 20090036451Abstract: The present invention relates to compounds and methods for inducing neuronal differentiation in normal neural stem cells and brain cancer stem cells. The methods may take place in vitro, such as in isolates from the adult mammalian brain, or in vivo. Compounds and methods described herein may find use in the treatment of neurodegenerative and psychiatric diseases, the repair and regeneration of the nervous system, and in treatment of neurologic malignancy.Type: ApplicationFiled: October 12, 2007Publication date: February 5, 2009Inventors: Jay Schneider, Jenny Hsieh, Douglas Frantz, Steven L. McKnight, Joseph M. Ready
-
Publication number: 20080140447Abstract: Embodiments of the present invention relate to methods and apparatuses serving to provide assurance that healthcare providers will receive payment for services rendered. In one embodiment, a payment card (or other portable consumer device) provides an extended authorization hold period (for example up to 21 days). This hold period allows the healthcare provider to request authorization for payment from the patient's credit, debit, FSA, HRA, or HSA payment card, submit the insurance claim, and then upon receipt of a health insurance carrier's Explanation of Benefits (EOB) within the hold period, submit for settlement only that amount actually due from the patient. In accordance with an alternative embodiment, pending receipt of the EOB from the insurer, the healthcare provider flags a transaction in a point-of-sale (POS) terminal device or server for storage and delayed submittal over an electronic payment network.Type: ApplicationFiled: June 8, 2007Publication date: June 12, 2008Inventors: Stacy Pourfallah, Janet Pruitt, Douglas Frantz, Roxanna Kayoumi
-
Publication number: 20060183897Abstract: Biaryl substituted triazole compounds represented by Formula I, II or III, or pharmaceutically acceptable salts thereof, and a process for making such compounds and salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, epilepsy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, and bipolar disorder, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds.Type: ApplicationFiled: March 12, 2004Publication date: August 17, 2006Inventors: Prasun Chakravarty, Michael Fisher, Brenda Palucki, Min Park, William Parsons, Bishan Zhou, James Carey, Douglas Frantz, Michael Kress, Damian Weaver
-
Publication number: 20050119261Abstract: Biaryl substituted triazole compounds represented by Formula I, II or III, or pharmaceutically acceptable salts thereof, and a process for making such compounds and salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, epilepsy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, and bipolar disorder, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds.Type: ApplicationFiled: March 12, 2004Publication date: June 2, 2005Inventors: Prasun Chakravarty, Michael Fisher, Jeffrey Fisher, Brenda Palucki, Min Park, William Parsons, Bishan Zhou, James Carey, Douglas Frantz, Michael Kress, Damian Weaver